The 20 Best Fragile X Syndrome Doctors Near Me in Ann Arbor, MI

Peter K. Todd, M.D., Ph.D., is an assistant professor in the Department of Neurology in the University of Michigan Medical School.Dr. Todd earned his Bachelor of Science degree in 1994 from the University of California, San Diego. He then entered the Medical Science Training Program at the University of Wisconsin at Madison, where he completed his doctorate in 2002 and medical degree in 2004. His Ph.D research focused on synaptic defects in Fragile X Syndrome, a common inherited cause of cognitive impairment in children.He completed his internship and residency at the Hospital of the University of Pennsylvania in Philadelphia. While there, he did research on the role of the ubiquitin proteasome system and autophagy in Spinal and Bulbar Muscular Atrophy, a polyglutamine disorder, and Fragile X Tremor Ataxia Syndrome (FXTAS). He came to the U-M in 2008 for a clinical and research fellowship in movement disorders and neurogenetics.Todd joined the U-M faculty in 2010 as an assistant professor in movement disorders and neurogenetics, working in the laboratory of Henry L. Paulson, M.D., Ph.D., in the Center for Neurodegenerative Research.His current research is focused on the mechanisms underlying RNA-mediated neurodegeneration in FXTAS and myotonic dystrophy, and how these mechanisms may overlap and inform our understanding of other neurodegenerative disorders. He also sees patients with movement disorders and inherited neurological disease.Dr. Todd has received several academic awards, including a Howard Hughes Undergraduate Research Fellowship, the Francis M. Forester Prize for promise as an academic neurologist, the Samuel Ziritzky Prize for most outstanding research by a neurology resident at Penn and prizes for excellence in research at the International Conference on Unstable Microsatellites in Human Disease, and the U-M neuroscience day. Most recently, Dr Todd received the S. Weir Mitchell Alliance award from the American Academy of Neurology which each year recognizes one early investigator physician scientist who has made important contributions to basic science in neurological disorders.A member of the American Medical Association and the American Academy of Neurology, he has served as an ad-hoc reviewer for the Journal of Biological Chemistry, Neurology, Proceedings of the National Academy of Sciences, Neuron, Science and Human Molecular Genetics.His bibliography includes several peer-reviewed papers, editorials, book reviews and chapters, abstracts and online. Dr. Todd is rated as an Elite provider by MediFind in the treatment of Fragile X Syndrome. He is also highly rated in 49 other conditions, according to our data. His clinical expertise encompasses Fragile X Syndrome, Fragile XE Syndrome, Hereditary Ataxia, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Dr. Todd is board certified in Neurology.

Jack M. Parent, M.D., is a professor of neurology, director of the Neurodevelopment and Regeneration Laboratory, and co-director of the Comprehensive Epilepsy Center in the University of Michigan Medical School.His current research interests include neural stem cell transplantation to treat brain injury and neurodegeneration, and the modification of adult neural stem cells to promote brain repair after stroke or prevent epilepsy.Dr. Parent earned a Bachelor of Arts degree, with distinction, in human biology from Stanford University and his medical degree from the Yale University School of Medicine. He completed a medical internship and neurology residency at the University of California, San Francisco (UCSF), where he was selected chief resident. He stayed at UCSF for clinical fellowship training in epilepsy and clinical neurophysiology, and postdoctoral training in neuroscience research.An internationally recognized research leader in the fields of neural stem cell biology, regeneration after brain injury and epilepsy, Dr. Parent established the Neurodevelopment and Regeneration Laboratory at the U-M in 2000.Dr. Parent is a member of the Epilepsy Foundation of America Research Council, the Medical Advisory Board of the Global Ischemia Foundation, the Independent Science Review Panel of the New Jersey Commission on Brain Injury Research, and the National Scientific Advisory Council of the American Federation for Aging Research. He also serves as an associate editor of Neuroscience Letters, and is on the editorial boards of Experimental Neurology and Epilepsy Currents.He has received several awards for his research, including a Junior Investigator Award from the American Epilepsy Society, a Paul Beeson Physician Faculty Scholars in Aging Award, a Dreifuss-Penry Epilepsy Award from the American Academy of Neurology, and a Grass Foundation Award in Neuroscience from the American Neurological Association. Dr. Parent is rated as an Experienced provider by MediFind in the treatment of Fragile X Syndrome. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Myoclonic Epilepsy, Epilepsy, Epilepsy with Myoclonic-Atonic Seizures, and Dravet Syndrome. Dr. Parent is board certified in Neurology and Clinical Neurophysiology.

Sami Barmada, M.D., Ph.D. is an assistant professor of neurology at the University of Michigan Medical School. His clinical interests center around patients with dementia and motor neuron disease, and he sees patients at the Cognitive Disorders Clinic in the University of Michigan’s East Ann Arbor location.His research focuses on the pathologic overlap between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), and how we can take advantage of the convergence to identify new and effective therapies for these devastating disorders.After graduating from the University of Pittsburgh, Pennsylvania, in 1998 with a major in Molecular Biology, Biochemistry, and a focus in Conceptual Foundations of Medicine, Dr. Barmada went on to the Medical Scientist Training Program at Washington University in St. Louis School of Medicine. For his graduate work, he constructed a transgenic mouse model of Creutzfeldt-Jacob disease with Dr. David Harris, and used these animals to track the deposition of misfolded prion protein within the nervous system of infected animals. For this work, Dr. Barmada earned earned the Poletsky Award from the Alzheimer’s Disease Research Center in St. Louis, Missouri, and was elected as a Olin Medical Scientist Fellow at Washington University School of Medicine.Dr. Barmada received his M.D. and Ph.D. in 2006, and completed an Internal Medicine internship at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Missouri, before moving to the University of California, San Francisco (UCSF), Medical Center for his residency in Neurology. Dr. Barmada served one year as Chief Resident in the Department of Neurology, focusing on resident education. He was also a house-staff nominee to the Alpha-Omega-Alpha honor society. During his residency, Dr. Barmada became involved in research with Dr. Steve Finkbeiner of the Gladstone Institutes, a pioneer in neuronal models of neurodegenerative disease and novel technologies to study these models. Dr. Barmada finished his residency in 2010 and spent one year working with Dr. Finkbeiner as a research fellow, before becoming a Staff Scientist at the Gladstone Institutes and a Clinical Instructor at UCSF. In 2013, Dr. Barmada became an Assistant Professor of Neurology at the University of Michigan, where he divides his time between the Cognitive Disorders Clinic and the laboratory. Dr. Barmada is rated as an Advanced provider by MediFind in the treatment of Fragile X Syndrome. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Frontotemporal Dementia, and Dementia. Dr. Barmada is board certified in Neurology.

Christina Sloan is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Ann Arbor, Michigan. Dr. Sloan is rated as an Advanced provider by MediFind in the treatment of Fragile X Syndrome. She is also highly rated in 115 other conditions, according to our data. Her clinical expertise encompasses Chromosome 6q Duplication, Chromosome 8p Deletion, Delayed Growth, and Fragile XE Syndrome. Dr. Sloan is board certified in Medical Biochemical Genetics and Clinical Genetics & Genomics.

Maysa Hamade, M.D., is a pediatric neuroimmunologist and clinical instructor in the division of pediatric neurology. Dr. Hamade completed medical school at Wayne State University School of Medicine in Detroit, MI in 2015 and, in 2020, completed the child neurology residency program at the University of Michigan Health C.S. Mott Children’s Hospital. She then went on to complete a 1-year multiple sclerosis fellowship at the University of Michigan and a 3-month observership of the pediatric neuroimmunology department at the Children’s Hospital of Philadelphia, both of which equip Dr. Hamade to diagnose and treat a wide variety of neuroimmunological conditions, including rare conditions. Dr. Hamade is rated as an Experienced provider by MediFind in the treatment of Fragile X Syndrome. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Rasmussen Encephalitis, Anti-NMDA Receptor Encephalitis, Encephalitis, and GAPO Syndrome. Dr. Hamade is board certified in Neurology W/Spec Qual Child Neuro.

Mark Hannibal is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Ann Arbor, Michigan. Dr. Hannibal is rated as an Experienced provider by MediFind in the treatment of Fragile X Syndrome. He is also highly rated in 166 other conditions, according to our data. His clinical expertise encompasses Aase Syndrome, CHARGE Syndrome, Cockayne Syndrome Type 2, and Hennekam Syndrome. Dr. Hannibal is board certified in Clinical Genetics & Genomics.

Dr. Lee earned her M.D. from Ross University School of Medicine in 2013, and completed Pediatric Residency at Ascension St. John Hospital in Grosse Point, MI, where she served as a Chief Pediatric Resident during her final year of residency. She completed Categorical Medical Genetics Residency at the University of Michigan in 2019. Following this she accepted a dual faculty position as a Clinical Lecturer in the Department of Pediatrics and Department of Internal Medicine for one year, before returning to Fellowship in 2020 to complete additional dedicated training in Medical Biochemical Genetics. After completion of Medical Biochemical Genetics Fellowship, she resumed her faculty position as a Clinical Assistant Professor in 2021. She is board certified in Pediatrics, and in Clinical and General Genetics.She has a dual faculty appointment in the Department of Pediatrics and the Department of Internal Medicine. As a faculty member in the Department of Pediatrics, she sees patients in the Pediatric Genetics and Biochemical Genetics Clinics, in addition to the newly created Multidisciplinary Genetics of Hearing Loss Clinic. As a faculty member in the Department of Internal Medicine, she sees patients in the Adult Medical Genetics and Cancer Genetics Clinics, in addition to patients with atypical diabetes and/or lipodystrophy in collaboration with MEND.In addition to her clinical responsibilities, Dr. Lee also enjoys spending time teaching and discussing various aspects of genetics with fellows, pediatric residents, medical students, and genetic counseling students. Dr. Lee is rated as an Experienced provider by MediFind in the treatment of Fragile X Syndrome. She is also highly rated in 138 other conditions, according to our data. Her clinical expertise encompasses Biotinidase Deficiency, Delayed Growth, Beta-Ketothiolase Deficiency, and Triple X Syndrome. Dr. Lee is board certified in Pediatrics, Clinical Genetics & Genomics, and Medical Biochemical Genetics.

Vikram Shakkottai is a Neurologist practicing medicine in Ann Arbor, Michigan. Dr. Shakkottai is rated as an Advanced provider by MediFind in the treatment of Fragile X Syndrome. He is also highly rated in 72 other conditions, according to our data. His clinical expertise encompasses Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, Spinocerebellar Ataxia Type 1, and Drug Induced Dyskinesia.

Henry L. Paulson, M.D., Ph.D., is the Lucile Groff Professor of Neurology for Alzheimer's Disease and Related Disorders in the Department of Neurology at the University of Michigan. Dr. Paulson joined the U-M faculty in 2007, and he currently directs the Michigan Alzheimer’s Disease Center (MADC) and co-direct the U-M Protein Folding Diseases Initiative.Dr. Paulson received his medical degree and doctorate in Cell Biology from Yale University in 1990. He then completed a neurology residency and neurogenetics/movement disorders fellowships at the University of Pennsylvania. In 1997, he joined the Neurology faculty at the University of Iowa, where he remained until 2007.Dr. Paulson's research and clinical interests concern the causes and treatment of age-related neurodegenerative diseases, with an emphasis on polyglutamine diseases, Alzheimer's disease and frontotemporal dementia. In 1997, his lab described abnormal protein aggregates in the polyglutamine diseases, which now are recognized as a pathological hallmark in this important class of inherited diseases. Using test tube, cell-based and animal models, he has contributed to advances in the understanding of various neurodegenerative diseases. His lab also has helped pioneer the use of gene silencing methods as potential therapy for the many neurological disorders caused by toxic mutant genes.Nationally, Dr. Paulson has directed popular courses at the American Academy of Neurology meetings, serves on the scientific advisory boards of numerous disease-related national organizations, and is past Chair of the Board of Scientific Counselors at the National Institute for Neurological Disorders and Stroke at the National Institutes of Health.Among his awards, Dr. Paulson is an Ellison Medical Foundation New Scholar in Aging, a semifinalist for the W.M. Keck Foundation Young Scholars in Medical Research, and a recipient of the Paul Beeson Physician Faculty Scholar in Aging Award from the American Federation for Aging Research. Dr. Paulson is rated as an Experienced provider by MediFind in the treatment of Fragile X Syndrome. He is also highly rated in 41 other conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia Type 3, Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, and Drug Induced Dyskinesia. Dr. Paulson is board certified in Neurology.

Amelia Heston is a Neurologist practicing medicine in Ann Arbor, Michigan. Dr. Heston is rated as an Experienced provider by MediFind in the treatment of Fragile X Syndrome. She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Parkinson's Disease, Movement Disorders, Chorea, Deep Brain Stimulation, and Thrombectomy. Dr. Heston is board certified in Neurology.